Actively Recruiting
Phase II Study of Serplulimab with Platinum-based Chemotherapy Before Surgery or Radiotherapy in Limited-stage Small Cell Lung Cancer
Led by Guangdong Provincial People's Hospital · Updated on 2025-04-04
45
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety and effectiveness of serplulimab combined with platinum-containing chemotherapy as a pre-surgery treatment for patients with limited-stage small cell lung cancer LS-SCLC at stages II to IIIB N2. This Phase II clinical trial is open-label and conducted across multiple centers in China, aiming to improve outcomes for patients by assessing the response to this induction therapy before surgery or radiotherapy. Participants will receive four cycles of serplulimab combined with etoposide and either carboplatin or cisplatin. After completing these treatment cycles, a multidisciplinary team will decide whether the patient undergoes surgery or radical radiotherapy. This study focuses on managing LS-SCLC using this combined approach followed by local treatment to potentially improve cancer control. During the trial, researchers will monitor participants closely through imaging assessments every two cycles, evaluate pathological response within two weeks after surgery, and follow up regularly for up to two years. They will measure outcomes such as the pathological complete response rate, objective response rate, event-free survival, and overall survival. Safety assessments and laboratory tests will be performed to ensure participant well-being throughout the study period.
CONDITIONS
Brief Title
Study of Serplulimab Plus Chemotherapy as Neoadjuvant Therapy for Limited-stage Small Cell Lung Cancer (LS-SCLC)
Research Team
C
Chen Huang, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here